Takeda Pharmaceutical broke into the list of top 20 publicly traded innovative global pharmaceutical companies based on market capitalization (Market Cap) during the first quarter (Q1), according to Global Data.
London/UK — Takeda is the new entrant in the list of the top 20 innovative global pharmaceutical companies, replacing Biogen. Takeda’s merger with Shire coupled with strong growth in drugs such as Azilva (Azilsartan), which reported a 36% increase in sales in Q1 2019, saw its revenues almost double from the fourth quarter (Q4) 2018 to Q1 2019. Takeda’s Market Cap during Q1 2019 grew to $ 63.4 billion, at the back of its takeover of Irish pharmaceuticals firm Shire Plc.
The top 20 pharma companies reported an aggregated Maket Cap of $ 2.63 trillion in Q1 2019, a growth of 6.2 % compared to $ 2.47 trillion as on 31 December 2018 (Q4 2018). Of the top 20,15 pharma companies reported quarter-on-quarter (QoQ) Market Cap growth, with six of them, Takeda (grew by 141.8 %), Celgene (37.1 %), Novo Nordisk (17 %), Novartis (14 %) Merck (13 %) and F. Hoffmann-La Roche (12.7 %), registering double digit growth.
This data can be found in Global Data’s Pharmaceutical Intelligence Center Financials Database. Celgene Corp’s share price grew from $ 64.09 in Q4 2018 to $ 87.45 at the end of Q1 2019, following its impending merger with Bristol-Myers Squibb Co.
Novo Nordisk too reported significant improvement in its share price, which closed at DKK 348.4 ($ 51.4) as on Q1 2019, against DKK 297.9 ($ 44) at the end of Q4 2018. The rally in share price was due to its strong performance in diabetes care and obesity markets, and positive regulatory approvals helped Novartis to expand its Market Cap.
Other notable movements include Roche moving up a place to second in the ranking, with Pfizer slipping a place to third.
Roche was favorably benefited from key blockbuster drugs such as Ocrevus (Ocrelizumab), which registered 23 % growth; and others such as Kadcyla (Trastuzumab Emtansine) and Hemlibra (emicizumab-kxwh), which saw 16 % and 96 % growth, respectively, during the period.
Among the five pharma companies which suffered Market Cap decline in Q1, Abb Vie registered more than 10 % QoQ decline as a result of the weakening European sales of its arthritis medication Humira following the introduction of biosimilar competition.